Market Overview

UPDATE: Goldman Sachs Upgrades Bruker Corporation to Buy on Operational Improvements

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research

Goldman Sachs raised its rating on Bruker Corporation (NASDAQ: BRKR) from Neutral to Buy and raised its price target from $13 to $19.

Goldman Sachs commented, "We upgrade shares of Bruker (BRKR) to Buy from Neutral and raise our 12-month price target to $19 (from $13), which implies 40% upside. After underperforming Tools peers by 1000bp YTD, we see a turnaround story for 2013 with healthy organic growth, margin expansion, and an attractive risk/reward profile coupled with the following catalysts: (1) better-than-expected strength in core end markets, (2) pending detail on long-term margin expansion plans, and (3) low expectations/valuation that sets up a “laggards to leader” trade."

Bruker Corporation closed at $13.61 on Friday.

Latest Ratings for BRKR

Sep 2015Morgan StanleyInitiates Coverage onEqual-weight
Aug 2015Cantor FitzgeraldInitiates Coverage onHold
May 2015William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters